Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook

Core Insights - Valneva SE reported preliminary unaudited full-year 2025 revenue of €174.7 million, including €157.9 million in product sales, which is in line with guidance [4][5] - The company anticipates a transformative year in 2026 with Phase 3 data for its Lyme disease vaccine candidate expected in the first half of the year [5][10] - Valneva's Chief Executive Officer, Thomas Lingelbach, has had his contract renewed for an additional three years, ensuring continuity in leadership [5][10] 2025 Financial Results - Total revenues for 2025 were €174.7 million, compared to €169.6 million in 2024, reflecting a year-over-year growth of approximately 0.6% [5][7] - Product sales decreased to €157.9 million from €163.3 million in 2024, a decline of 3.3%, with third-party sales dropping by 42.3% to €19.2 million [5][7] - Excluding third-party sales, product sales increased by 6.7% year-over-year, with a 9% increase at constant exchange rates [7] Cash Position and Financial Guidance - The company reported a strong year-end cash position of €109.7 million as of December 31, 2025, down from €168.3 million in 2024, following successful debt refinancing [5][7] - For 2026, total revenues are expected to range between €155-170 million, with product sales projected between €145-160 million, reflecting continued growth in established brands but a decline in third-party sales [5][10] - Operating cash burn is expected to decline further in 2026 while maintaining strategic R&D investments [5] R&D Pipeline and Future Prospects - The first Phase 3 data readout for the Lyme disease vaccine candidate is anticipated in the first half of 2026, with regulatory submissions planned by Pfizer, contingent on positive results [5][10] - Valneva is also progressing with its tetravalent shigella vaccine candidate, with a decision on further development expected in the second half of 2026 [5][10] - The company aims to enhance its R&D pipeline with differentiated vaccine candidates targeting areas of high unmet medical need [5][10]